Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Current Liabilities (2023 - 2026)

Prelude Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $41.7 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 110.85% to $41.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $41.7 million, a 110.85% increase, with the full-year FY2025 number at $53.0 million, up 106.68% from a year prior.
  • Total Current Liabilities hit $41.7 million in Q1 2026 for Prelude Therapeutics, down from $53.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PRLD hit a ceiling of $53.0 million in Q4 2025 and a floor of $17.6 million in Q1 2024.
  • Historically, Total Current Liabilities has averaged $26.4 million across 4 years, with a median of $22.0 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: dropped 18.15% in 2025 and later surged 110.85% in 2026.
  • Tracing PRLD's Total Current Liabilities over 4 years: stood at $21.8 million in 2023, then increased by 17.46% to $25.6 million in 2024, then surged by 106.68% to $53.0 million in 2025, then dropped by 21.27% to $41.7 million in 2026.
  • Business Quant data shows Total Current Liabilities for PRLD at $41.7 million in Q1 2026, $53.0 million in Q4 2025, and $18.2 million in Q3 2025.